Efficacy and Safety of Paclitaxel-Based PD-1/PD-L1 Immunotherapies for Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis

Efficacy and Safety of Paclitaxel-Based PD-1/PD-L1 Immunotherapies for Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis

Background: Triple negative breast cancer (TNBC) is a deadly subtype of breast cancer with limited treatment options. Currently, programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have become the first choice for breast cancer immunotherapies. Despite paclitaxel being considered...

Full description

Saved in:

Bibliographic Details
Main Authors:	Youran Dai, Tianyin Ruan, Wenhui Yang, Shan Liu, Jiahao Chen, Yingying Fang, Qiushuang Li
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-12-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	https://doi.org/10.1177/11795549241308072
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Correlation analysis of DLG5 and PD-L1 expression in triple-negative breast cancer
by: Jingmin Che, et al.
Published: (2025-01-01)

Impact of Neoadjuvant Therapy on PD-L1 Expression in Triple-Negative Breast Cancer and Correlation with Clinicopathological Factors
by: Nevena Ilieva, et al.
Published: (2024-11-01)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
by: Brian Alexander, et al.
Published: (2020-10-01)

Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment
by: Tangyi Wang, et al.
Published: (2025-01-01)

PD-L1 antibodies-armed exosomal vaccine for enhanced cancer immunotherapy by simultaneously in situ activating T cells and blocking PD-1/PD-L1 axis
by: Xinyue Dai, et al.
Published: (2022-12-01)

Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer
by: Cong Chen, et al.
Published: (2022-12-01)

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
by: Jing Zhang, et al.
Published: (2022-12-01)

Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
by: Madhusudan Roy, et al.
Published: (2024-03-01)

Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer
by: Jia-xin Qiao, et al.
Published: (2024-12-01)

Inhibition of triple-negative breast cancer growth via delphinidin-mediated suppression of the JAK2/STAT3/PD-L1 pathway
by: Xiaoping Yu, et al.
Published: (2024-12-01)

Current perspectives on tertiary lymphoid structures and PD-1/PD-L1 signaling pathway in the immunotherapy of hepatocellular carcinoma
by: Hao-Dong QIAO, et al.
Published: (2023-10-01)

From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment
by: Fang-Ju Huang, et al.
Published: (2025-12-01)

Letter to the editor, “Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – Implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy.”
by: Geetha Shanmugam
Published: (2024-09-01)

Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy
by: Yogesh Godiyal, et al.
Published: (2024-12-01)

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
by: Menglei Jin, et al.
Published: (2024-11-01)

Tumor microenvironment and immunotherapy for triple-negative breast cancer
by: Zijie Guo, et al.
Published: (2024-12-01)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
by: Rangarirai Makuku, et al.
Published: (2021-01-01)

Clinical Significance of Negative Costimulatory Molecule PD-1/PD-L1 on Peripheral Blood Regulatory T Cell Levels among Patients with Pulmonary Tuberculosis
by: Chenchen Yang, et al.
Published: (2022-01-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy
by: Jin Li, et al.
Published: (2024-12-01)

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors
by: Anna Hernández‐Prat, et al.
Published: (2025-01-01)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
by: Valerie Chew, et al.
Published: (2020-10-01)

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
by: Yago Pico de Coaña, et al.
Published: (2020-05-01)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
by: Razelle Kurzrock, et al.
Published: (2020-05-01)

Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy
by: Sandy El Bitar, et al.
Published: (2018-01-01)

Obesity diminishes response to PD-1-based immunotherapies in renal cancer
by: Peng Li, et al.
Published: (2020-10-01)

Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review
by: Feng Zhao, et al.
Published: (2021-12-01)

Dissecting the link between PD-1/PD-L1-based immunotherapy and cancer pain: mechanisms, research implications, and artificial intelligence perspectives
by: Marco Cascella, et al.
Published: (2024-12-01)

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
by: Yimin Zheng, et al.
Published: (2023-10-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

Relationship between the ultrasound features of different molecular subtypes of breast cancer and positive PD-1/PD-L1 expression
by: Ruiqian Yan, et al.
Published: (2025-02-01)

Prevotellaceae Modulates Colorectal Cancer Immune Microenvironment to Assist Anti-PD-L1 Immunotherapy
by: Song Xu, et al.
Published: (2024-12-01)

Programmed Cell Death Ligand 1 (PD-L1) and major Histocompatibility Complex Class I (MHC Class I) Expression Patterns and Their Pathologic Associations in triple-Negative Breast Cancer
by: Kaewkedsri P, et al.
Published: (2025-02-01)

Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
by: Jesse Haramati, et al.
Published: (2025-02-01)

Exploring PD-1 methylation in oral cancer: A crucial frontier in immunotherapy
by: Prasad Monisha, et al.
Published: (2024-03-01)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
by: Lin Liu, et al.
Published: (2020-10-01)

Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
by: Chenyue Qian, et al.
Published: (2018-01-01)

Methionine restriction promotes the polarization of macrophages towards M1 and the immunotherapy effect of PD-L1/PD-1 blockades by inhibiting the secretion of MIF by gastric carcinoma cells
by: Lin Xin, et al.
Published: (2025-01-01)

Long-Term Response to PD-1 and CTLA-4 Blockade in an SCLC Patient with Negative PD-L1 Expression on Biopsy: A Case Report
by: Marco Cefalì, et al.
Published: (2023-03-01)

PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
by: Mengjia Song, et al.
Published: (2024-12-01)